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Health Insurance database, 2009), costs of care in community and in institution 
(French National Assembly on AD management, report 2005). Results were reported 
in EUR 2009. Health-related utilities were obtained from preceding published eco-
nomic evaluations in AD (Getsios et al 2001). Costs and QALYs were discounted at 
annual rates of 0% (base-case analysis), 3% and 5%. Deterministic and probabilistic 
sensitivity analyses were carried out to test the robustness of model assumptions. 
RESULTS: Over the seven-year time horizon, patients treated with ChEI monotherapy 
spent on average 41.6 months before institutionalization. Overall costs were c72,469 
(health care system perspective) or c89,735 (societal perspective). QALYs were esti-
mated at 2.36. Memantine as adjunct therapy to ChEI was associated with a longer 
time to nursing home of 8.9 months, QALYs gains of 0.19 and a cost saving of c5900 
(health care system perspective) or c2200 (societal perspective), i.e. a dominant treat-
ment scenario versus ChEI monotherapy. CONCLUSIONS: This economic evaluation 
suggest that, from both a health care system and a societal perspective, memantine as 
adjunct therapy to ChEI is a cost-effective strategy in the management of AD patients 
compared with ChEI monotherapy.
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48-HOUR INFUSION OF METHYLPREDNISOLONE IS A COST-EFFECTIVE 
INTERVENTION FOR TRAUMATIC SPINAL CORD INJURY
Schwartz G, Ruiz C, Ferreira JC, Rotstein OD, Hoch JS, Coyte PC
University of Toronto, Toronto, ON, Canada
OBJECTIVES: Methylprednisolone sodium succinate (MP) is an acute therapeutic 
option for traumatic spinal cord injury (SCI). a pivotal multicentre randomized control 
trial reported modest functional improvements and increased clinical complications 
associated with an extended dose regimen of MP for 48 hours (48h-MP) versus a 
limited dose regimen of MP for 24 hours (24h-MP), resulting in clinical ambiguity 
between 48h-MP and 24h-MP. Concerning the health care burden imposed by this 
devastating form of neurotrauma, an economic assessment comparing the beneﬁ ts 
either MP regimen imparts has never been reported. We performed a cost-effectiveness 
analysis (CEA) of 48h-MP compared with 24h-MP to determine their impact on direct 
health care costs for this patient population. METHODS: A decision tree model, 
incorporating motor improvement and complication frequencies reported by the Third 
National Acute Spinal Cord Injury Study and utility scores (QALYs) obtained from 
an Australian cohort, measured outcomes and effects at 6 and 12 months post-injury. 
Survival data, direct health care expenditures and complication costs associated with 
SCI and MP intervention were obtained from published epidemiological and survey 
data. CEA was performed from the health care payer’s perspective, discounted at a 
rate of 4% annually with a lifetime horizon. Distributions of the incremental cost-
effectiveness ratio between the interventions were determined by Monte Carlo simula-
tion. The model was validated with sensitivity analyses by varying costs and outcome 
comparators. RESULTS: As a result, 48h-MP dominates 24h-MP, providing higher 
QALYs at lower costs. The lower costs associated with 48h-MP intervention was 
$35,703 per patient lifecycle. Earlier motor improvement maintained at 1-year post-
injury was a key variable favouring 48h-MP intervention, despite complications asso-
ciated with this dosing regimen. CONCLUSIONS: To conclude, 48h-MP is the 
cost-effective intervention for SCI in comparison to 24h-MP, wherein the former 
results in modestly improved motor function, an effect which is maintained up to at 
least 1-year post-injury.
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OBJECTIVES: To conduct a German economic evaluation of natalizumab compared 
to other disease modifying drugs (DMD) in relapsing-remitting Multiple Sclerosis (MS) 
from a societal perspective. METHODS: A Markov model was designed to compare 
costs and outcomes of Natalizumab (Nb), other DMD (interferon-beta, glatiramer 
acetate) and best supportive care (BSC). The expanded disability status scale (EDSS) 
and the line of treatment were used to deﬁ ne the distinctive Markov States. Transition 
probabilities for progression, treatment switches and withdrawals were derived from 
clinical studies and literature. German real-life treatment data of MS-patients under 
DMD were collected retrospectively (N = 554) and used to validate assumptions and 
conduct sensitivity analyses. Cost data and quality of life estimates were taken from 
a European burden of MS study. a time horizon of 30 years and annual discount rates 
of 3% for costs and outcomes were chosen. RESULTS: Treatment with Nb resulted 
in 8.13 avoided relapses over 30 years, and in 2.36 avoided relapses under other DMD. 
After 30 years, the proportion of surviving patients at a low state of disease (incl. 
EDSS 4) was 59% for the Nb group, 31% for the other DMD and 8% for patients 
in the BSC group. The average MS related costs over 30 years were estimated at 
c847,160 for Nb, c816,139 for other DMD, and c627,701 for BSC. Cost per quality 
adjusted life-year (QALY) was c60,938 for Nb, c64,481 for other DMD and c53,911 
for BSC. The incremental cost-effectiveness of Nb compared to other DMD was 
c24,919 per QALY. CONCLUSIONS: MS is a resource intense disease due to its 
chronic course and its severe impact on patients’ daily life. Long term analysis suggests 
that even treatment without DMD is expensive and leads to considerable inferior 
clinical outcomes. Treatment with DMD improves the situation of patients, with 
Natalizumab showing the highest efﬁ cacy and best cost-effectiveness ratio.
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IS ROPINIROLE-PROLONGED RELEASE A COST-SAVING TREATMENT 
OPTION IN PARKINSON’S DISEASE?
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OBJECTIVES: Parkinson’s Disease (PD) is both a chronic and progressive neurode-
generative disorder. a 24-hour prolonged release tablet (PR) of the dopamine agonist 
ropinirole was introduced next to three daily doses of ropinirole immediate release 
(IR). a randomized controlled trial (PREPARED) was conducted, comparing ropini-
role-IR with ropinirole-PR. Ropinirole-PR signiﬁ cantly improved the off-time and this 
analysis assesses the costs-effectiveness of the ropinirole-PR in PD patients who are 
not adequately controlled on L-dopa compated to ropinirole-IR. METHODS: A 
Markov-health-state-transition model was used with health states combining off-time 
≤25% and >25% per day, Hoehn & Yahr stages 2–5 and problematic dyskinesias. 
Time horizons are 5 years and lifelong. Costs and effects were discounted by 4% and 
1,5% respectively. Healthcare perspective was taken, covering direct costs related to 
medication, consults, nursing and patient care including informal care, based on an 
ongoing Dutch observational study in PD (IMPACT study). Clinical outcomes from 
the PREPARED-trial are extrapolated based on literature assumptions. Results are 
presented as incremental costs and QALY’s gained. Both univariate and probabilistic 
sensitivity analyses (PSA) were performed. RESULTS: Ropinirole-PR was associated 
with lower L-dopa use, less off-time and less problematic dyskinesias. This resulted 
in incremental QALY gains of 0.125 and 0.336 over respectively 5 years and lifetime. 
The health care costs per H&Y-stage increased with disease severity and amounted 
c916, c1,492, c11,295 and c11.295 for stage 2 to 5 over 6 months. Treatment with 
ropinirole-PR was more costly than ropinirole-IR with a difference of c7.266 over 5 
years and c17.773 over lifetime. Treatment with ropinirole-PR however reduced 
medical costs by c8,059 over 5 years and c69,532 over lifetime compared with rop-
inirol-IR, mainly due to reduced dyskinesia occurrence. Sensitivity analysis conﬁ rmed 
the robustness of the model. CONCLUSIONS: Patient-functioning and quality of life 
were improved with ropinirole-PR realizing cost-savings to the health care budget as 
compared to treatment with ropinirole-IR.
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COST-EFFECTIVENESS OF TRANSDERMAL PATCH (ROTIGOTINE) IN 
PATIENTS WITH PARKINSON DISEASE IN MEXICO
Aguirre A, Benitez A, Bierschwale H
UCB MEXICO, Mexico City, D.F., Mexico
BACKGROUND: Parkinson’s Disease (PD) is a central nervous system disorder 
caused by progressive deterioration of brain areas that produce dopamine. Oral 
dopaminergic therapies control the symptoms of the disease, but these require three 
or more times daily doses, so it is associated with poor compliance or adherence, 
which affects the overall efﬁ cacy and costs in health. OBJECTIVES: To analyze the 
cost-effectiveness of rotigotine versus pramipexole in patients with PD in Mexico. 
METHODS: We conducted an economic evaluation. The alternatives to compare were 
rotigotine 4, 6, 8 and 12  mg administered once daily versus pramipexole 3 mg/d and 
another scenario versus pramipexole 4.5 mg/d. The perspective is the Mexican Social 
Security Institute. The model included the cost of drug acquisition and management 
of adverse events (AE) for a 22 weeks period. The measure of efﬁ cacy was compliance 
or adherence to treatment, as a direct comparison study of rotigotine versus prami-
pexole demonstrated non-inferiority between the two alternatives. RESULTS: The 
compliance rate for rotigotine was 81% vs. 61% pramipexole. The costs were 
US$748, US$920, US$1113 and US$1701 for rotigotine 4, 6, 8 and 12 mg/d respec-
tively, compared with US$670 and US$967 for pramipexole 3 and 4.5 mg/d. The cost 
per successfully treated patient was lower for rotigotine 4, 6 and 8 mg/d (US$923, 
US$1 136 and US$1374, respectively) than with pramipexole 4.5 mg/d (US$1585). 
Rotigotine 4, 6, 8 and 12 mg/d were found to be a highly cost-effective strategy 
compared with pramipexole 3 and 4.5 mg/d, according to WHO criteria. CONCLU-
SIONS: The results of this analysis suggest that the use of rotigotine in patients with 
PD, represents a highly cost-effective strategy or cost saving for the public health 
institutions in Mexico. Rotigotine is an innovative alternative for easy administration 
(transdermal).
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OBJECTIVES: This study aimed to compare the cost-effectiveness (CE) of Bridion® 
(sugammadex) with neostigmine and spontaneous recovery (SR) approach in the 
reversal of neuromuscular blockade (NMB) induced by rocuronium/vecuronium, 
during anesthesia. METHODS: CE analysis (CEA) was performed by solving back 
the decision tree that included pathways starting with residual NMB and followed by 
hypoxia and pulmonary complications deﬁ ned as “aspiration, atelectasis and/or pneu-
monia” in patients, in whom NMB was induced by rocuronium/vecuronium. Bridion 
was compared with neostigmine and SR approach. Primary analysis parameters that 
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were used as denominators in the calculation of incremental CE ratios (ICER) are 
decreased frequencies of mild hypoxia, severe hypoxia and pneumonia. RESULTS: 
Frequencies of residual NMB were estimated as 51.2% 44.6% and 0.4% in SR, 
neostigmine and Bridion groups, respectively. Hypoxia rate was calculated as 27.4% 
and 11.4% in patients with and without residual NMB. Frequencies of pneumonia 
were 17.2% and 5.9% in patients with and without residual NMB. Percentage of 
patients without any complication was found to be 88.0% in Bridion group, while it 
was 73.8% and 75.7% in SR and neostigmine groups. The costs of complications 
were 126.45c and 114.56c in SR and neostigmine groups, while it was only 34.93c in 
Bridion® group. When medication cost was added, the total cost rose to 114.62c in 
Bridion® group, which was still lower than the total costs of SR and neostigmine 
groups. The rate of severe hypoxia was estimated as 7.9% in Bridion® group, while 
it was 13.5% and 12.7% in SR and neostigmine groups, respectively. Pneumonia was 
seen in 1.2% of the patients in Bridion® group, while the frequencies of pneumonia 
were 9.4% and 8.3% in SR and neostigmine groups. CONCLUSIONS: Bridion® was 
found to be dominant to both SR and neostigmine groups, in terms of decrease in 
frequencies of hypoxia and pulmonary complications.
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COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/
ENTACAPONE IN TREATMENT OF PARKINSON DISEASE
Yagudina R, Kulikov AU, Serpik VG
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/
Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. 
Standard therapy was presented by Levodopa and Carbidopa. METHODS: The cost-
effectiveness study was carried conducted. Effectiveness was measured in DALYs. 
Time horizont for cost-effectiveness analysis was 2 years. a 3% discount rate was 
used. 1 EUR = 40 RUB. RESULTS: LCE provided beneﬁ ts in effectiveness compared 
to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. 
Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy 
presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 
68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard 
therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 
EUR) yearly according to disease progression grade. Indirect costs, including GDP 
losses due to temporary disability and payments for temporary disability, were 14 372 
RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The cost-
effectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for 
standard therapy it was 258 326 RUB (6 458 EUR) per DALY. CONCLUSIONS: LCE 
demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard 
Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over 
standard therapy in terms of pharmacoeconomic evaluation.
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THE IMPACT OF COHORT SELECTION ON COST-EFFECTIVENESS 
RESULTS IN MULTIPLE SCLEROSIS
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OBJECTIVES: Adherence to cost-effectiveness analytic guidelines requires careful 
assessment of clinical trial results to ensure the most appropriate cohort data selection. 
This study examines the impact of cohort selection on the results of the Goldberg, et 
al. 2009 cost-effectiveness study of disease-modifying therapies (DMTs) in multiple 
sclerosis (MS). METHODS: Using intent–to-treat (ITT) two-year data from pivotal 
trials, Goldberg compared cost per relapse avoided of ﬁ rst-line DMTs. However, there 
are important differences in the ITT cohorts among the trials. Due to lower than 
expected subject drop-out rates, the interferon beta-1a IM (INF-b-1a-IM) trial was 
able to meet its primary endpoint with a reduced sample size and a decision was made 
to terminate the trial early. This resulted in almost half of the 301 ITT (or “all-
patient”) cohort being on study drug for less than two years. a second, “two-year” 
172 patient cohort consisted of patients who had completed two years on drug 
therapy. Goldberg used the INF-b-1a-IM “all-patient” cohort in his cost study. To 
test the impact of this cohort selection, we recreated Goldberg’s model using the “all-
patient” relapse rate (0.67 for INF-b-1a-IM vs. 0.82 for placebo) and then substituted 
the “two-year” cohort data (relapse rate of 0.61 for INF-b-1a-IM vs. 0.90 for placebo) 
and compared results. RESULTS: This study’s cost per relapse avoided was 45% lower 
for INF-b-1a-IM while the results for the other DMTs were comparable to those 
reported by Goldberg. Ranked from most to least cost-effective, the model results were 
$77,980 for INF-b-1a-IM, $80,121 for interferon beta-1a SC, $86,572 for interferon 
beta-1b, and $87,767 for glatiramer. CONCLUSIONS: Our analysis demonstrates the 
importance of cohort selection in cost-effectiveness analyses in MS. By selecting 
comparable cohort data from patients who had completed at least two years on study 
drug, we found that INF-b-1a-IM had the lowest cost per relapse avoided of all ﬁ rst-
line DMTs.
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ECONOMIC EVALUATION OF NATALIZUMAB IN THE TREATMENT OF 
RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN 
COUNTRIES
Brennig C, Walter E, Schöllbauer V
Institute for Pharmaeconomic Research, Vienna, Austria
OBJECTIVES: Multiple sclerosis (MS) is an inﬂ ammatory, neurodegenerative condi-
tion of central nervous system with prevalence of 1 Million worldwide (age at ﬁ rst 
manifestation 20–40 years). MS may lead to permanent disability and early retirement 
even in young adults. The purpose of this analysis was to provide an economic assess-
ment of relapsing-remitting MS-treatment with Natalizumab versus Interferons and 
Copolymer in 4 European countries (Austria, Czech Republic, Slovakia, Slovenia). 
METHODS: The analysis was performed using a Markov model. The model allows 
a treatment switch due to relapse. Efﬁ cacy assessment was based on the outcome 
measure “relapse-free patients”. Costs were captured for the year 2010. Resource use 
was determined from results of a survey conducted by the Austrian MS Society and 
accurately reﬂ ects the therapeutic approach. Resource use of Czech Republic, Slovakia 
and Slovenia was determined via country-speciﬁ c research. Where country speciﬁ c 
data could not be captured, Austrian data was adjusted via Purchasing Power Parities 
(PPP). The study time horizon was 2 years. The analysis was performed from the 
perspective of the health care system of the 4 European countries. RESULTS: In Czech 
Republic the average cost of the therapy algorithm Natalizumab amount to c33,835 
per patient within the time horizon of 2 years versus c22,896 (Interferon) and c21,256 
(Copolymer). a patient successfully treated with Natalizumab accounts for c56,525 
compared to c70,190 (Interferon) and for c87,555 (Copolymer). In Slovakia a relapse-
free patient values c60,357 (Natalizumab) versus c58,043 (Interferon) and c19,921 
(Copolymer). a relapse-free patient in Slovenia values c59,108 (Natalizumab) versus 
c66,202 (Interferon) and c84,207 (Copolymer). In Austria a relapse-free patient values 
c58,423 (Natalizumab) versus c71,906 (Interferon) and c89,591 (Copolymer). CON-
CLUSIONS: In Czech Republic, Slovenia, and Austria, treatment of MS with Natali-
zumab is more cost-effective than Interferon resp. Copolymer 1 therapy. Switching to 
effective and more expensive alternatives does not account for higher health care costs.
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in 
patients with uncontrolled partial-onset seizures. METHODS: The model simulated 
the treatment pathway of a hypothetical cohort of 1000 patients over 2 years from 
the perspectives of the National Health Service (NHS) in Scotland and the Spanish 
Healthcare System (SNS) in 2008. a decision tree was split into four phases of six 
months each during which patients can become seizure free, experience a seizure 
reduction (responder deﬁ ned as ≥50% reduction in seizures), or withdraw due to 
non-response. The standard therapy arm included carbamazepine, lamotrigine, leve-
tiracetam, topiramate, and valproate. The likelihood of being in a particular health 
state has been estimated from clinical data. The cost of general practitioner visits, 
outpatient visits, hospitalizations and emergency department visits were included. 
Costs and utility values attached to various health states were taken from the published 
literature. RESULTS: Lacosamide adjunctive therapy was associated with 6730 
avoided seizures and a gain of 38 quality adjusted life-years (QALYs), compared to 
the standard therapy arm within the two-year timeframe. Treatment with lacosamide 
was associated with a cost of £113 and c107 per seizure avoided, and £20,017 and 
c22,771 per QALY gained versus standard therapy in Scotland and Spain, respectively. 
Results calculated for 6-, 12- and 18-month follow-up showed respective incremental 
cost-utility ratios of £23,479, £21,422 and £20,998 in Scotland, and c23,771, c20,703 
and c21,778 in Spain. Using a willingness-to-pay threshold of £30,000 per QALY, 
80% of the simulations in Scotland and 74.2% in Spain fell below this value after 2 
years of treatment. CONCLUSIONS: Lacosamide was shown to be a cost-effective 
adjunctive treatment in patients with uncontrolled partial-onset epilepsy in Scotland 
and Spain.
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IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE IN SWEDEN
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BACKGROUND: Advanced Parkinson’s disease (APD) severely impacts the quality 
of life (QoL) for both patients and their caregiver and is associated with high health 
care and societal costs. The treatment options for those patients are limited. Duodenal 
levodopa infusion (DLI), an orphan drug, has shown to restore symptom control and 
to improve QoL substantially for both patients and their carers. OBJECTIVES: To 
evaluate the cost-utility of DLI versus standard treatment (including oral treatment 
and subcutaneous dopamine agonists) in patients with advanced PD in Sweden. 
METHODS: A stochastic Markov-based simulation model was developed. Health was 
described by 12 health states reﬂ ecting 4 categories of “OFF” time and 3 severity 
stages as measured by the Hoehn & Yahr scale. The clinical effect for both treatment 
arms was derived from published clinical trials; costs and QoL utilities were taken 
from an interim analysis of the ongoing DAPHNE study. The base case simulated 5 
years with costs/effects discounted by 3%. The societal perspective was adopted. 
RESULTS: The model estimated an improvement from 0.68 to 1.30 QALYs and a 
cost increase from 1,410,643 (c147,108) to SEK 1,674,295 (c174,603) for DLI versus 
standard treatment, leading to an incremental cost-effectiveness ratio (ICER) of 
around SEK 420,000 (c43,800) per QALY gained. The ICER for nearly 90% of the 
cohorts fell below SEK 655,000 (c68,306), the willingness-to-pay threshold often cited 
